Clinical Trials
9 trialsNCT01458366 2025-04-30
Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide
Thomas Jefferson University
Phase 1/2 Completed
NCT01352312 2025-04-29
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
Thomas Jefferson University
Phase 1 Terminated
NCT01060384 2023-10-04
Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT01171378 2018-04-25
CHOP-OR
University of Oxford
Phase 2 Completed
NCT01263418 2015-10-12
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT01119794 2015-08-26
Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab
Brown University
Phase 2 Terminated
NCT01221103 2011-09-13
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Southern Europe New Drug Organization
Phase 1/2 Unknown
NCT01125787 2011-07-20
Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab
Nevada Cancer Institute
Phase 2 Terminated
NCT01131247 2011-07-20
PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab
Nevada Cancer Institute
Phase 2 Withdrawn